Steinfurt

This research aims to compare the effectiveness and remaining refractive error of two types of phakic toric intraocular lenses in patients with moderate to high myopia and astigmatism. The study also evaluates and compares the safety of the EYECRYLTM Phakic Toric lens versus the Visian4 Toric Implantable Contact Lens in this patient group. Phakic intraocular lenses are clear lenses surgically placed in the eye without removing the natural lens, helping to improve uncorrected vision by focusing light correctly on the retina. Participants will be randomly assigned to receive one of two treatments the Eyecryl Phakic Toric intraocular lens or the Visian4 Toric Implantable Contact Lens. Both lenses are designed to correct myopia and astigmatism and are implanted either in the anterior or posterior chamber of the eye. The study involves surgical placement of these lenses to assess their performance and safety over time. During the study, participants will attend all scheduled follow-up visits to monitor visual outcomes and safety. Researchers will measure the mean residual refractive error six months after lens implantation as the primary outcome. Safety assessments and other evaluations will also be conducted to track the lenses effects. The study started in October 2021 and is expected to continue until February 2027, with ongoing monitoring of participants vision and eye health.

Researchers are collecting real-world data on the use of assistive devices, medicines, and other healthcare measures in patients with Amyotrophic Lateral Sclerosis ALS, Spinal Muscular Atrophy SMA, and other neurological diseases. The study aims to understand clinical practice by gathering patient-reported outcomes and evidence from daily healthcare. It includes information on clinical characteristics, medical history, and treatment satisfaction. The study collects data on various treatments and supports such as ventilation therapy, nutrition support, and innovative drugs like Tofersen, Nusinersen, and Risdiplam. It also gathers information on symptomatic drugs and genetic markers relevant to these neurological conditions. Patient questionnaires and clinical scales are used to capture treatment effectiveness and patient expectations. Participants provide information over a long-term period, with the primary outcome focusing on systematic recording of neurological treatment and patient evaluations via specific questionnaires for up to 10 years. Data collected include biomarker levels, genetic mutation status, and clinical assessment scales like the ALS Functional Rating Scale-Revised ALSFRS-R. This observational registry study involves no interventional treatments and aims to monitor healthcare use and patient experiences comprehensively.